Early Experiences With Nirsevimab: Perspectives From Newborn Hospitalists
- Elena Aragona; Neha Joshi; Krista Birnie; Poj Lysouvakon; Rakhi Basuray
Access Resources
About
This article discusses the implementation of newly developed nirsevimab into clinical practice. Approved in July 2023, it is costly and has supply issues. Hospitals struggle with high demand and limited availability, leading to unequal access. Pediatricians are urged to work together to ensure all eligible infants receive the treatment despite these obstacles. The American Academy of Pediatrics suggests strategies like bundled payments for newborn care and better planning based on past vaccine rollouts. The situation highlights the need for improved public-private partnerships and advocacy efforts.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.